ONCOLOGY COMMERCIAL DISEASE AREA LEADER
SOLID TUMOR TARGETED THERAPIES
As Oncology Commercial Disease Area Leader, Solid Tumor Targeted Therapies, Amy is the global oncology strategic leader responsible for the commercial optimization of the solid tumor disease area portfolio. In addition, Amy and her team lead the commercial strategy for the Immune Therapy, Lung Cancer Initiative and Colorectal Cancer Interception efforts.
Amy has over 20 years of experience in the pharmaceutical industry, all in oncology, where she has covered both solid and hematologic malignancies throughout her career. Her commercial roles have spanned multiple functions, including sales, in-line marketing, new business development and global strategic marketing. She has been with Janssen for 15 years. Prior to her current role, Amy served as the New Products Leader for Oncology at Merck for six years, with strategic commercial responsibility for the early oncology portfolio.
Amy holds a master’s degree in chemistry from State University of New York (SUNY) Stony Brook.